Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Bone Biologics Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
BBLG
Nasdaq
2836
www.bonebiologics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Bone Biologics Corporation
Bone Biologics Announces Closing of $5.0 Million Public Offering
- Jun 30th, 2025 2:10 pm
Bone Biologics Announces Pricing of $5.0 Million Public Offering
- Jun 27th, 2025 7:10 am
Traders Digest Fed's Preferred Inflation Gauge as US Equity Futures Gain Pre-Bell
- Jun 27th, 2025 7:02 am
BBLG Moves Toward Commercialization
- Jun 27th, 2025 5:22 am
Bone Biologics Files Patent Application for Bone Regeneration Technology
- Jun 27th, 2025 5:00 am
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
- Jun 26th, 2025 2:20 pm
BBLG Splits to Advance
- Jun 11th, 2025 4:36 am
Bone Biologics Announces 1-for-6 Reverse Stock Split
- Jun 6th, 2025 6:00 am
BBLG Entering Critical Stage in Good Shape
- May 13th, 2025 6:15 am
BBLG Continues Crucial Testing
- Feb 27th, 2025 4:17 am
BBLG in Good Shape as Testing Continues
- Nov 15th, 2024 4:03 am
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
- Oct 21st, 2024 6:00 am
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 4th, 2024 6:00 am
LifeNet launches newest bone allograft gel with Johnson & Johnson
- Aug 28th, 2024 5:13 am
BBLG: Controls Costs and Advances Trials
- Aug 12th, 2024 6:25 am
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
- Aug 2nd, 2024 6:00 am
OTC Markets Hosts Virtual Investor Presentation with Jeff Frelick, CEO and President of Bone Biologics, and Deina Walsh, CFO, with Brad Sorensen, Senior Analyst at Zacks SCR
- Jul 11th, 2024 10:28 am
Scroll